Clinical trial
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
NCT00061425 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00061425 |
|---|---|
| Title | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG |
| Official title | Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Lymphoma, B-Cell |
| Intervention type | Drug |
| Interventions | radiolabeled epratuzumab |
| Start date | Aug 1, 2000 |
| Primary completion | Nov 1, 2007 |
| First posted | May 28, 2003 |
| Last update posted | Aug 19, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: